Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis

In the high-octane world of biotechnology, success is often measured by the narrowest of margins. But for Dr. Ian Nisbet, CEO of Melbourne-based Cartherics, the mission is defined by a gap so large it has become a “tragic” outlier in modern medicine: the chronic underfunding of women’s health.

Ovarian cancer, often called the “silent killer,” claims 200,000 lives annually, while endometriosis—a debilitating condition affecting 190 million women—remains essentially without a cure. Nisbet, a veteran of the sector who has helped bring two FDA-approved oncology drugs to market, isn’t just looking to fill this gap; he’s looking to bridge it with a single, “off-the-shelf” biological weapon.

For years, the medical community viewed endometriosis and ovarian cancer as distinct challenges. However, a landmark 2024 study revealed a terrifying correlation: women with severe, untreated endometriosis are up to 20 times more likely to develop ovarian cancer.

“There is a natural progression probably due to prolonged inflammation,” Nisbet explains, noting that the two diseases share overlapping biological targets. This discovery is the cornerstone of Cartherics’ strategy. By targeting a specific protein called TAG-72—a marker found on both late-stage ovarian tumors and endometriotic lesions—the company is developing a “like-for-like” therapy that can transition from the oncology ward to the chronic care clinic.

Traditional cell therapies (autologous) are bespoke and prohibitively expensive, often costing upwards of $500,000 per patient because they require extracting and modifying a patient’s own cells. Cartherics is ditching this “one-product-one-patient” model in favor of an allogeneic—or “off-the-shelf”—approach.

Using induced Pluripotent Stem Cells (iPSCs) as a “master bank,” Cartherics creates Natural Killer (NK) cells. These are the body’s “special forces,” naturally pre-programmed to destroy abnormal cells without the need for complex activation.

In an industry where many “virtual” biotechs outsource their most critical work, Cartherics has taken a different path. In Melbourne’s Notting Hill, the company has built its own $4 million state-of-the-art cleanroom facility.

This “discovery-to-clinic engine” allows the team—which includes IVF pioneer Professor Alan Trounson—to handle everything from genetic engineering to clinical-grade manufacturing under one roof. This operational leaness gives Cartherics a level of quality control and speed that many of its international peers lack.

After a decade of “heavy lifting” and $50 million in investment, Cartherics is entering its “hot zone”. The company is currently seeking $15 million (USD) to propel its lead candidate, CTH-401, through its most significant milestone yet:

“Now is a great time because there’s all that investment gone in, and now we’re going to capture the value,” Nisbet says. With 21 granted patents and a further 29 pending applications in our own portfolio, complemented by over 90 licensed patent filings and a clear roadmap into a multi-billion dollar market, Cartherics is positioned as a counter-cyclical opportunity for those looking to back a world-class team solving a global crisis.

Cartherics recently participated in Emergence 2026 in Sydney, the message to the market is clear: the science is proven, the facility is built, and the clinical “rubber” is about to hit the road.